Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lyra Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Lyra Therapeutics, Inc.

LYRA

Lyra Therapeutics, Inc.

About Lyra Therapeutics, Inc.

Lyra Therapeutics is a biotech company developing localized, bioabsorbable drug delivery systems for chronic rhinosinusitis (CRS). Its lead product, LYR-210, is a nasal implant delivering six months of anti-inflammatory therapy, aiming to improve symptoms and reduce surgical interventions. The company focuses on in-office procedures, targeting unmet needs in ENT markets, with a proprietary technology platform and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lyra Therapeutics, Inc.

1
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports $28.9 Million Net Loss and Workforce Reduction Amid Financial Challenges

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports Decreased Revenue and Ongoing Net Losses in Latest Financial Filing

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports Decrease in Collaboration Revenue and Improved Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports Significant Decline in Q1 2025 Financial Performance

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports $93.4 Million Net Loss for 2024 Amid Restructuring and Trial Setbacks

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lyra Therapeutics, Inc. Lyra Therapeutics Reports Significant Financial Challenges, Net Loss, and Compliance Issues

Via official filing (AI summary) | over 1 year ago | 0 comments